Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone619-323-2200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.24 million
Profitability
Miscellaneous
Employees53
OptionableOptionable
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.06. The biopharmaceutical company earned $0.12 million during the quarter, compared to analysts' expectations of $0.30 million. Otonomy had a negative net margin of 6,983.40% and a negative return on equity of 54.24%. View Otonomy's Earnings History.
When is Otonomy's next earnings date?
What price target have analysts set for OTIC?
4 brokerages have issued twelve-month price targets for Otonomy's shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate Otonomy's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 372.6% from the stock's current price. View Analyst Price Targets for Otonomy.
What is the consensus analysts' recommendation for Otonomy?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.
Has Otonomy been receiving favorable news coverage?
News headlines about OTIC stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Otonomy earned a news impact score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include TapImmune (MRKR), Emisphere Technologies (EMIS), Kala Pharmaceuticals (KALA), Verastem (VSTM), Savara (SVRA), Synlogic (SYBX), Kamada (KMDA), Paratek Pharmaceuticals (PRTK), MannKind (MNKD), Syros Pharmaceuticals (SYRS), Acer Therapeutics (ACER), Avid Bioservices (CDMO), LifeVantage (LFVN), resTORbio (TORC) and Dova Pharmaceuticals (DOVA).
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
- Dr. David Allen Weber, Pres, CEO & Director (Age 59)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
- Dr. Kathie M. Bishop, Chief Scientific Officer (Age 53)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
Who are Otonomy's major shareholders?
Otonomy's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (9.93%), 683 Capital Management LLC (3.59%), Pura Vida Investments LLC (2.93%), D. E. Shaw & Co. Inc. (2.81%), BlackRock Inc. (2.75%) and Millennium Management LLC (0.30%). View Institutional Ownership Trends for Otonomy.
Which major investors are selling Otonomy stock?
OTIC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Millennium Management LLC, Barclays PLC, D. E. Shaw & Co. Inc., Connor Clark & Lunn Investment Management Ltd. and Bank of America Corp DE. View Insider Buying and Selling for Otonomy.
Which major investors are buying Otonomy stock?
OTIC stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., Pura Vida Investments LLC, 683 Capital Management LLC, BlackRock Inc. and Acadian Asset Management LLC. View Insider Buying and Selling for Otonomy.
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $2.01.
How big of a company is Otonomy?
Otonomy has a market capitalization of $61.57 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.
What is Otonomy's official website?
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (NASDAQ OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
